In the North American pharmaceutical industry, there were 44 private equity deals announced in Q2 2023, worth a total value of $12.4bn, according to GlobalData’s Deals Database. The $7.1bn institutional buy-out (ibo) syneos health by Elliott Investment Management, Patient Square Capital and Veritas Capital was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in North America increased by 313% in Q2 2023 compared with the previous quarter’s total of $3bn and rose by 317% as compared to Q2 2022. Related deal volume increased by 19% in Q2 2023 versus the previous quarter and was 63% higher than in Q2 2022.
The top-ranked financial advisors supporting these private equity deals in North America in Q2 2023 were Cantor Fitzgerald; Moelis & Co; WBC Holdings with 4, 4, 3 deals respectively.
The top-ranked legal advisors supporting these private equity deals in North America Q2 2023 were Kirkland & Ellis; Goodwin Procter; Ropes & Gray with 6, 5, 4 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.